Astral Systems, a deep-tech company based in Hallen, South Gloucestershire, has secured £23 million in Series A funding to develop medical isotopes for cancer diagnosis and treatment, expand production of its modular reactors, and advance fusion research. The company, which is pioneering a new type of nuclear fusion technology, aims to bring one or more medical isotopes to market by 2027.
Funding and Investors
The investment round was led by Mercia Ventures, with support from prominent tech investors including Tees River, Daphni, and Blast Club, alongside previous stakeholders Speedinvest and Playfair Capital. This brings the total raised by Astral Systems to more than £28 million.
Talmon Firestone, chief executive and co-founder of Astral Systems, said: “We are rewriting how we approach fusion and, in doing so, redefining what it means to be a fusion company. This is evident in our novel technology and its near-term applications in modern medicine, as well as facilitating the search for hybrid energy. With this new funding we can accelerate our ambition of building a profitable, impactful fusion business, and build on the momentum of the past 12 months with the backing of our investors.”
Technology and Facilities
Astral Systems’ modular reactors use so-called "multi-state fusion technology," which the company says allows the reactors to operate with greater efficiency and at lower cost than traditional ones. The company was founded by Mr Firestone, a serial entrepreneur, and nuclear physicist Dr Tom Wallace-Smith.
The company is developing a new high-energy facility at the former Berkeley Power Station in Gloucestershire. It intends to be running multiple reactors at full capacity by the end of the year and to bring one or more medical isotopes to market in 2027. Over the following years, it aims to manufacture dozens more reactors and expand their use across other commercial sectors.
Medical Applications and Revenue
Lee Lindley, who led the investment on behalf of Mercia Ventures, said: “We’re incredibly proud to have led this investment into Astral Systems and are excited about working with Talmon and Tom. Astral’s technology has the potential to transform the manufacturing and supply of medical isotopes, which are vitally important for diagnostic and therapeutic purposes. Astral Systems is a perfect example of the bold ideas that Mercia likes to back.”
Astral Systems has already generated more than £3 million in revenue from commercial and research contracts. It is currently working with partners from industry and academia on a number of projects to produce radioisotopes and advanced nuclear fuels.
Workforce Expansion
The company, which currently employs 23 people, plans to increase its team to more than 40 staff by the end of the year. The latest investment supports this growth as Astral Systems scales its operations to meet the demand for medical isotopes and fusion technology.
